Veraxa Biotech AG - Post de-SPAC (VRXA) Total Non-Current Liabilities (2024 - 2025)
Veraxa Biotech AG - Post de-SPAC's (VRXA) quarterly Total Non-Current Liabilities came in at $112.6 million in Q4 2025, up 92.74% year-over-year from $58.4 million in Q4 2024, and up 92.74% quarter-over-quarter from $58.4 million in Q4 2024.
Powered by 
Analysis
Veraxa Biotech AG - Post de-SPAC (VRXA) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Veraxa Biotech AG - Post de-SPAC (VRXA) has reported Total Non-Current Liabilities for 2 consecutive years, with $112.6 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 92.74% year-over-year to $112.6 million in Q4 2025; TTM through Dec 2025 was $112.6 million, a 92.74% increase from a year earlier, with the FY2025 full-year figure at $112.6 million, up 92.74% from the prior year.
- Total Non-Current Liabilities was $112.6 million for Q4 2025 at Veraxa Biotech AG - Post de-SPAC, up from $58.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $112.6 million in Q4 2025 and troughed at $58.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Veraxa Biotech AG - Post de-SPAC | 23.88 Mn | 20.47 Mn | - | 112.57 Mn |